Distribution and determinants of C-reactive protein in the older adult population: European prospective investigation into cancer-norfolk study

European Journal of Clinical Investigation

Volumn 43, Issue 9, 2013, Pages 899-911

  Ahmadi Abhari, Sara ^a   Luben, Robert N ^a   Wareham, Nicholas J ^b   Khaw, Kay Tee ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b INSTITUTE OF METABOLIC SCIENCE   (United Kingdom)

Author keywords

Ageing; Body size; C reactive protein; Distribution; Epidemiology; Inflammation

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; AGING; ALCOHOL CONSUMPTION; ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BODY MASS; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; EDUCATIONAL STATUS; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SEX DIFFERENCE; SMOKING; SOCIAL CLASS; WAIST CIRCUMFERENCE;

AGEING; BODY SIZE; C-REACTIVE PROTEIN; DISTRIBUTION; EPIDEMIOLOGY; INFLAMMATION;

ADULT; AGED; AGING; ANTHROPOMETRY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHRONIC DISEASE; CROSS-SECTIONAL STUDIES; ENGLAND; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LIFE STYLE; MALE; MENOPAUSE; MIDDLE AGED; NEOPLASMS; REFERENCE VALUES;

EID: 84881654235     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/eci.12116     Document Type: Article

References (57)

1. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004;350:1387-97.
2. Agrawal A. CRP after 2004. Mol Immunol 2005;42:927-30.
3. Kaptoge S, Di AE, Lowe G, Pepys MB, Thompson SG, Collins R et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.
4. Lin CC, Kardia SL, Li CI, Liu CS, Lai MM, Lin WY et al. The relationship of high sensitivity C-reactive protein to percent body fat mass, body mass index, waist-to-hip ratio, and waist circumference in a Taiwanese population. BMC Public Health 2010;10:579.
5. Wang CS, Sun CF. C-reactive protein and malignancy: clinico-pathological association and therapeutic implication. Chang Gung Med J 2009;32:471-82.
6. Hussain SP, Harris CC. Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007;121:2373-80.
7. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol Biomarkers Prev 2006;15:381-4.
8. Il'yasova D, Colbert LH, Harris TB, Newman AB, Bauer DC, Satterfield S et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Prev 2005;14:2413-8.
9. Siemes C, Visser LE, Coebergh JW, Splinter TA, Witteman JC, Uitterlinden AG et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam Study. J Clin Oncol 2006;24:5216-22.
10. Chaturvedi AK, Caporaso NE, Katki HA, Wong HL, Chatterjee N, Pine SR et al. C-reactive protein and risk of lung cancer. J Clin Oncol 2010;28:2719-26.
11. Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 2009;27:2217-24.
12. Gunter MJ, Stolzenberg-Solomon R, Cross AJ, Leitzmann MF, Weinstein S, Wood RJ et al. A prospective study of serum C-reactive protein and colorectal cancer risk in men. Cancer Res 2006;66:2483-7.
13. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004;291:585-90.
14. Aleksandrova K, Jenab M, Boeing H, Jansen E, Bueno-de-Mesquita HB, Rinaldi S et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. Am J Epidemiol 2010;172:407-18.
15. Windgassen EB, Funtowicz L, Lunsford TN, Harris LA, Mulvagh SL. C-reactive protein and high-sensitivity C-reactive protein: an update for clinicians. Postgrad Med 2011;123:114-9.
16. Chen TH, Gona P, Sutherland PA, Benjamin EJ, Wilson PW, Larson MG et al. Long-term C-reactive protein variability and prediction of metabolic risk. Am J Med 2009;122:53-61.
17. Emberson JR, Whincup PH, Morris RW, Walker M, Lowe GD, Rumley A. Extent of regression dilution for established and novel coronary risk factors: results from the British Regional Heart Study. Eur J Cardiovasc Prev Rehabil 2004;11:125-34.
18. Day N, Oakes S, Luben R, Khaw KT, Bingham SWelch A, Wareham N. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999;80(Suppl 1):95-103.
19. Shohaimi S, Luben R, Wareham N, Day N, Bingham S, Welch A et al. Residential area deprivation predicts smoking habit independently of individual educational level and occupational social class. A cross sectional study in the Norfolk cohort of the European Investigation into Cancer (EPIC-Norfolk). J Epidemiol Community Health 2003;57:270-6.
20. Simera I, Moher D, Hoey J, Schulz KF, Altman DG. A catalogue of reporting guidelines for health research. Eur J Clin Invest 2010;40:35-53.
21. Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med 2005;352:1611-3.
22. Ford ES, Giles WH, Mokdad AH, Myers GL. Distribution and correlates of C-reactive protein concentrations among adult US women. Clin Chem 2004;50:574-81.
23. Ford ES, Giles WH, Myers GL, Mannino DM. Population distribution of high-sensitivity C-reactive protein among US men: findings from National Health and Nutrition Examination Survey 1999-2000. Clin Chem 2003;49:686-90.
24. Albert MA, Glynn RJ, Buring J, Ridker PM. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study). Am J Cardiol 2004;93:1238-42.
25. Imhof A, Frohlich M, Loewel H, Helbecque N, Woodward M, Amouyel P et al. Distributions of C-reactive protein measured by high-sensitivity assays in apparently healthy men and women from different populations in Europe. Clin Chem 2003;49:669-72.
26. Yamada S, Gotoh T, Nakashima Y, Kayaba K, Ishikawa S, Nago N et al. Distribution of serum C-reactive protein and its association with atherosclerotic risk factors in a Japanese population: Jichi Medical School Cohort Study. Am J Epidemiol 2001;153:1183-90.
27. Zhao Y, Wang R, Ma X, Yan X, Zhang Z, He X et al. Distribution of C-reactive protein and its association with cardiovascular risk factors in a population-based sample of Chinese. Dis Markers 2010;28:333-42.
28. Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
29. Grace FM, Davies B. Raised concentrations of C reactive protein in anabolic steroid using bodybuilders. Br J Sports Med 2004;38:97-8.
30. Arcari A, Zito F, Di CA, De CA, Dirckx C, Arnout J et al. C reactive protein and its determinants in healthy men and women from European regions at different risk of coronary disease: the IMMIDIET Project. J Thromb Haemost 2008;6:436-43.
31. Lee YJ, Lee JH, Shin YH, Kim JK, Lee HR, Lee DC. Gender difference and determinants of C-reactive protein level in Korean adults. Clin Chem Lab Med 2009;47:863-9.
32. Camhi SM, Bray GA, Bouchard C, Greenway FL, Johnson WD, Newton RL et al. The relationship of waist circumference and BMI to visceral, subcutaneous, and total body fat: sex and race differences. Obesity 2011;19:402-8.
33. Kuk JL, Lee S, Heymsfield SB, Ross R. Waist circumference and abdominal adipose tissue distribution: influence of age and sex. Am J Clin Nutr 2005;81:s1330-4.
34. Maki KC, Rains TM, Bell M, Reeves MS, Farmer MV, Yasunaga K. Fat mass, abdominal fat distribution, and C-reactive protein concentrations in overweight and obese men and women. Metab Syndr Relat Disord 2011;9:291-6.
35. Thorand B, Baumert J, Doring A, Herder C, Kolb H, Rathmann W et al. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 2006;184:216-24.
36. Festa A, D'Agostino R Jr, Williams K, Karter AJ, Mayer-Davis EJ, Tracy RP et al. The relation of body fat mass and distribution to markers of chronic inflammation. Int J Obes Relat Metab Disord 2001;25:1407-15.
37. Lapice E, Maione S, Patti L, Cipriano P, Rivellese AA, Riccardi G et al. Abdominal adiposity is associated with elevated C-reactive protein independent of BMI in healthy nonobese people. Diabetes Care 2009;32:1734-6.
38. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-5.
39. Flegal KM, Shepherd JA, Looker AC, Graubard BI, Borrud LG, Ogden CL et al. Comparisons of percentage body fat, body mass index, waist circumference, and waist-stature ratio in adults. Am J Clin Nutr 2009;89:500-8.
40. Pou KM, Massaro JM, Hoffmann U, Vasan RS, Maurovich-Horvat P, Larson MG et al. Visceral and subcutaneous adipose tissue volumes are cross-sectionally related to markers of inflammation and oxidative stress: the Framingham Heart Study. Circulation 2007;116:1234-41.
41. Selvin E, Paynter NP, Erlinger TP. The effect of weight loss on C-reactive protein: a systematic review. Arch Intern Med 2007;167:31-9.
42. Brooks GC, Blaha MJ, Blumenthal RS. Relation of C-reactive protein to abdominal adiposity. Am J Cardiol 2010;106:56-61.
43. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 1999;19:972-8.
44. Kwok S, Charlton-Menys V, Pemberton P, McElduff P, Durrington PN. Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women. Maturitas 2006;53:439-46.
45. Walsh BW, Paul S, Wild RA, Dean RA, Tracy RP, Cox DA et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 2000;85:214-8.
46. Sezer OK, Erenus M, Yoldemir T. The impact of tibolone and hormone therapy on serum C-reactive protein, tumor necrosis factor-alpha and hepatocyte growth factor in postmenopausal women. Climacteric 2009;12:66-71.
47. van Baal WM, Kenemans P, Emeis JJ, Schalkwijk CG, Mijatovic V, van der Mooren MJ et al. Long-term effects of combined hormone replacement therapy on markers of endothelial function and inflammatory activity in healthy postmenopausal women. Fertil Steril 1999;71:663-70.
48. Koh KK, Ahn JY, Jin DK, Yoon BK, Kim HS, Kim DS et al. Effects of continuous combined hormone replacement therapy on inflammation in hypertensive and/or overweight postmenopausal women. Arterioscler Thromb Vasc Biol 2002;22:1459-64.
49. Silvestri A, Gebara O, Vitale C, Wajngarten M, Leonardo F, Ramires JA et al. Increased levels of C-reactive protein after oral hormone replacement therapy may not be related to an increased inflammatory response. Circulation 2003;107:3165-9.
50. Eilertsen AL, Hoibraaten E, Os I, Andersen TO, Sandvik L, Sandset PM. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis. Maturitas 2005;52:111-8.
51. Raitakari M, Mansikkaniemi K, Marniemi J, Viikari JS, Raitakari OT. Distribution and determinants of serum high-sensitive C-reactive protein in a population of young adults: the Cardiovascular Risk in Young Finns Study. J Intern Med 2005;258:428-34.
52. Volpato S, Pahor M, Ferrucci L, Simonsick EM, Guralnik JM, Kritchevsky SB et al. Relationship of alcohol intake with inflammatory markers and plasminogen activator inhibitor-1 in well-functioning older adults: the Health, Aging, and Body Composition study. Circulation 2004;109:607-12.
53. Albert MA, Glynn RJ, Ridker PM. Alcohol consumption and plasma concentration of C-reactive protein. Circulation 2003;107:443-7.
54. Imhof A, Woodward M, Doering A, Helbecque N, Loewel H, Amouyel P et al. Overall alcohol intake, beer, wine, and systemic markers of inflammation in western Europe: results from three MONICA samples (Augsburg, Glasgow, Lille). Eur Heart J 2004;25:2092-100.
55. Imhof A, Froehlich M, Brenner H, Boeing H, Pepys MB, Koenig W. Effect of alcohol consumption on systemic markers of inflammation. Lancet 2001;357:763-7.
56. Estruch R, Sacanella E, Badia E, Antunez E, Nicolas JM, Fernandez-Sola J et al. Different effects of red wine and gin consumption on inflammatory biomarkers of atherosclerosis: a prospective randomized crossover trial. Effects of wine on inflammatory markers. Atherosclerosis 2004;175:117-23.
57. Sierksma A, van der Gaag MS, Kluft C, Hendriks HF. Moderate alcohol consumption reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled intervention study. Eur J Clin Nutr 2002;56:1130-6.